started · updated
Zimmer Biomet to acquire Pacira BioSciences’ Iovera device
Zimmer Biomet has agreed to acquire the Iovera business from Pacira BioSciences in a deal valued at up to $140 million. The agreement includes an upfront payment of $70 million, with an additional $70 million available in revenue-based milestone payments through 2031.
The Iovera system utilizes cold therapy to provide targeted pain relief, offering a non-opioid alternative for patients with knee pain or those undergoing joint replacement surgery. The acquisition is intended to strengthen Zimmer Biomet’s orthopaedics portfolio and address the growing demand for non-opioid pain management technologies.
In separate financial news, Zimmer Biomet reported third-quarter 2026 results that exceeded Wall Street expectations. The company reported revenue of $2.06 billion, a 3.1% increase year-on-year, and an adjusted earnings per share of $1.90, which surpassed analyst consensus estimates. Following these results, management raised its full-year adjusted EPS guidance to a midpoint of $8.55.